{"title":"The role of strategy units in guiding research institutions through complexity.","authors":"Michela Giulia Bertero, Katrine Sonne-Hansen, Anna-Lynn Wegener, Teresa Sanchis","doi":"10.1038/s41591-026-04218-8","DOIUrl":"https://doi.org/10.1038/s41591-026-04218-8","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1038/s41591-025-04139-y
Aarthi Talla, Joao L. L. C. Azevedo, Muhammad Bilal Latif, Ana B. Enriquez, Gabriela Pacheco Sanchez, Adam N. Pelletier, Saswat Kumar Bal, Sangeeta Kumari, Viviane Schuch, Khader Ghneim, Ajantha Rhodes, Frank Maldarelli, Robert Yarchoan, Kathryn Lurain, Ramya Ramaswami, Elad Sharon, Bruce W. Hess, Leonard D’Amico, Javier Martinez-Picado, Nicolas Chomont, Sharon R. Lewin, Steven G. Deeks, Steven P. Fling, Martin A. Cheever, Thomas S. Uldrick, Ashish A. Sharma, Rafick-Pierre Sekaly
Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1–2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGFβ. Furthermore, among the 14 participants tracked to the end of treatment (ranging from 44 to 315 days after therapy initiation), nine display early induction and sustained expression of interferon-stimulated genes (ISGs), antiviral restriction factors and Toll-like receptor (TLR) signaling and a reduction in the HIV reservoir. Mapping these transcriptomic signatures across more than 1,000 public single-cell RNA sequencing datasets reveals that anti-PD-1-induced programs are present in subsets of across subsets of disease states, indicating that some people already display a heightened antiviral state. Together, these findings define immune pathways that help identify PLWH most likely to experience reservoir decay with anti-PD-1 therapy and suggest that sustained ISG activation may contribute to reservoir reduction and prevention of viral rebound upon ART interruption. ClinicalTrials.gov registration: NCT02595866 . A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic, cellular and cytokine changes related to immune checkpoint inhibitor treatment and identifies a signature associated with clinical response.
{"title":"Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy","authors":"Aarthi Talla, Joao L. L. C. Azevedo, Muhammad Bilal Latif, Ana B. Enriquez, Gabriela Pacheco Sanchez, Adam N. Pelletier, Saswat Kumar Bal, Sangeeta Kumari, Viviane Schuch, Khader Ghneim, Ajantha Rhodes, Frank Maldarelli, Robert Yarchoan, Kathryn Lurain, Ramya Ramaswami, Elad Sharon, Bruce W. Hess, Leonard D’Amico, Javier Martinez-Picado, Nicolas Chomont, Sharon R. Lewin, Steven G. Deeks, Steven P. Fling, Martin A. Cheever, Thomas S. Uldrick, Ashish A. Sharma, Rafick-Pierre Sekaly","doi":"10.1038/s41591-025-04139-y","DOIUrl":"10.1038/s41591-025-04139-y","url":null,"abstract":"Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1–2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGFβ. Furthermore, among the 14 participants tracked to the end of treatment (ranging from 44 to 315 days after therapy initiation), nine display early induction and sustained expression of interferon-stimulated genes (ISGs), antiviral restriction factors and Toll-like receptor (TLR) signaling and a reduction in the HIV reservoir. Mapping these transcriptomic signatures across more than 1,000 public single-cell RNA sequencing datasets reveals that anti-PD-1-induced programs are present in subsets of across subsets of disease states, indicating that some people already display a heightened antiviral state. Together, these findings define immune pathways that help identify PLWH most likely to experience reservoir decay with anti-PD-1 therapy and suggest that sustained ISG activation may contribute to reservoir reduction and prevention of viral rebound upon ART interruption. ClinicalTrials.gov registration: NCT02595866 . A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic, cellular and cytokine changes related to immune checkpoint inhibitor treatment and identifies a signature associated with clinical response.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"32 2","pages":"505-517"},"PeriodicalIF":50.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41591-025-04139-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146180935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1038/s41591-025-04152-1
PD-1 blockade reprograms both innate and adaptive immunity in people living with HIV and cancer, inducing interferon-driven antiviral responses that reduce the HIV reservoir. A pre-existing type I interferon signature predicts reservoir decline, whereas high TGFβ signaling opposes it, defining immune states that influence the outcome of PD-1 therapy.
{"title":"PD-1 blockade reprograms antiviral immunity and reduces the HIV reservoir","authors":"","doi":"10.1038/s41591-025-04152-1","DOIUrl":"10.1038/s41591-025-04152-1","url":null,"abstract":"PD-1 blockade reprograms both innate and adaptive immunity in people living with HIV and cancer, inducing interferon-driven antiviral responses that reduce the HIV reservoir. A pre-existing type I interferon signature predicts reservoir decline, whereas high TGFβ signaling opposes it, defining immune states that influence the outcome of PD-1 therapy.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"32 2","pages":"425-426"},"PeriodicalIF":50.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146181077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1038/s41591-026-04207-x
Baris R Mutlu, Sabrina C Civale, Joshua Diettrich, Neha Gupta, Thomas Barber, Mitchel Sayare, Alan S Penzias, Michael M Alper, Thomas L Toth, Ravi Kapur, Mehmet Toner, Denny Sakkas, Emre Ozkumur
Infertility is a global health challenge affecting millions worldwide, and in vitro fertilization (IVF) remains the main treatment option. The increasing demand for IVF necessitates innovations that improve access, efficiency and outcomes. To address this need, we developed a microfluidic device (FIND-Chip) that automates the isolation and denudation of oocytes from follicular fluid (FF), a critical step in IVF workflow. In a clinical study involving 582 patients from four IVF centers, FIND-Chip was utilized to perform automated oocyte recovery from FF and revealed that in more than 50% of the cases functional and mature oocytes are inadvertently discarded under current clinical practice. These undetected oocytes successfully developed into high-quality blastocysts, thereby substantially expanding the embryo pool available for patients' treatment. Notably, an oocyte that was retrieved by FIND-Chip from a clinically screened and discarded FF sample led to a live birth, highlighting the potential of microfluidic automation to enhance IVF success rates.
{"title":"Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization.","authors":"Baris R Mutlu, Sabrina C Civale, Joshua Diettrich, Neha Gupta, Thomas Barber, Mitchel Sayare, Alan S Penzias, Michael M Alper, Thomas L Toth, Ravi Kapur, Mehmet Toner, Denny Sakkas, Emre Ozkumur","doi":"10.1038/s41591-026-04207-x","DOIUrl":"https://doi.org/10.1038/s41591-026-04207-x","url":null,"abstract":"<p><p>Infertility is a global health challenge affecting millions worldwide, and in vitro fertilization (IVF) remains the main treatment option. The increasing demand for IVF necessitates innovations that improve access, efficiency and outcomes. To address this need, we developed a microfluidic device (FIND-Chip) that automates the isolation and denudation of oocytes from follicular fluid (FF), a critical step in IVF workflow. In a clinical study involving 582 patients from four IVF centers, FIND-Chip was utilized to perform automated oocyte recovery from FF and revealed that in more than 50% of the cases functional and mature oocytes are inadvertently discarded under current clinical practice. These undetected oocytes successfully developed into high-quality blastocysts, thereby substantially expanding the embryo pool available for patients' treatment. Notably, an oocyte that was retrieved by FIND-Chip from a clinically screened and discarded FF sample led to a live birth, highlighting the potential of microfluidic automation to enhance IVF success rates.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146181037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1038/s41591-026-04208-w
Felix Gerber, Giuliana Sanchez-Samaniego, Ravi Gupta, Thabo Ishmael Lejone, Thesar Tahirsylaj, Fabian Raeber, Mamakhala Chitja, Malebona Mathulise, Thuso Kabi, Mosoetsi Mokaeane, Malehloa Maphenchane, Manthabiseng Molulela, Makhebe Khomolishoele, Mota Mota, Sesale Masike, Matumaole Bane, Manthati Mofokeng, Mamoronts'ane Pauline Sematle, Retselisitsoe Makabateng, Madavida Mphunyane, Lebohang Sao, Mosa Tlahali, Malitaba Litaba, Dave Brian Basler, Kevin Kindler, Irene Ayakaka, Pauline Grimm, Thilo Burkard, Frédérique Chammartin, Alain Amstutz, Niklaus Daniel Labhardt
Access to hypertension care remains insufficient, particularly in remote rural areas in resource-limited settings. Community health workers (CHWs), lay providers living in the communities they serve, may help close this gap, but the effectiveness and safety of lay CHW-led hypertension care-including independent initiation and titration of medication-remain uncertain. We conducted a 1:1 cluster-randomized trial nested within the Community-Based Chronic Care Lesotho (ComBaCaL) cohort study in 103 rural villages in Lesotho. Following community-based hypertension screening, 547 nonpregnant adults with blood pressure (BP) ≥140/90 mm Hg were enrolled (274 control and 273 intervention). In intervention clusters, lay CHWs independently prescribed and titrated a fixed-dose combination of amlodipine and hydrochlorothiazide, guided by a mobile clinical decision support system. In control clusters, participants were referred to health facilities for standard care. The primary objective was to assess the effectiveness and safety of lay CHW-led care, with the primary outcome defined as BP <140/90 mm Hg at 12 months. In the intention-to-treat analysis (543 participants with 4 exclusions owing to intercurrent pregnancy), BP control was achieved by 156/271 (58%) versus 130/272 (48%) in intervention and control arms, respectively (adjusted odds ratio 1.52, 95% confidence interval 1.01 to 2.29, P = 0.046). A predefined complete case analysis yielded consistent results. No relevant differences in safety outcomes were observed. Among people with uncontrolled hypertension, lay CHW-led, CDSS-supported care was safe and more effective than referral to facility-based professional care. These findings support expanding first-line hypertension management by lay CHWs in remote, resource-limited settings. Clinicaltrials.gov registration: NCT05684055 .
获得高血压护理的机会仍然不足，特别是在资源有限的偏远农村地区。社区卫生工作者（chw），生活在他们服务的社区的非专业提供者，可能有助于缩小这一差距，但非专业chw领导的高血压护理的有效性和安全性-包括独立开始和滴定药物-仍然不确定。我们在莱索托103个乡村的社区慢性护理莱索托（ComBaCaL）队列研究中进行了1:1集群随机试验。在以社区为基础的高血压筛查后，547名血压(BP)≥140/90 mm Hg的未怀孕成人入组（对照组274名，干预组273名）。在干预集群中，在移动临床决策支持系统的指导下，基层chw独立开处方并滴定氨氯地平和氢氯噻嗪的固定剂量组合。在对照组中，参与者被转诊到卫生机构接受标准治疗。主要目的是评估非专业chw主导护理的有效性和安全性，主要结局定义为BP
{"title":"Lay community health worker-led care with mobile decision support for uncontrolled hypertension: a cluster-randomized trial.","authors":"Felix Gerber, Giuliana Sanchez-Samaniego, Ravi Gupta, Thabo Ishmael Lejone, Thesar Tahirsylaj, Fabian Raeber, Mamakhala Chitja, Malebona Mathulise, Thuso Kabi, Mosoetsi Mokaeane, Malehloa Maphenchane, Manthabiseng Molulela, Makhebe Khomolishoele, Mota Mota, Sesale Masike, Matumaole Bane, Manthati Mofokeng, Mamoronts'ane Pauline Sematle, Retselisitsoe Makabateng, Madavida Mphunyane, Lebohang Sao, Mosa Tlahali, Malitaba Litaba, Dave Brian Basler, Kevin Kindler, Irene Ayakaka, Pauline Grimm, Thilo Burkard, Frédérique Chammartin, Alain Amstutz, Niklaus Daniel Labhardt","doi":"10.1038/s41591-026-04208-w","DOIUrl":"https://doi.org/10.1038/s41591-026-04208-w","url":null,"abstract":"<p><p>Access to hypertension care remains insufficient, particularly in remote rural areas in resource-limited settings. Community health workers (CHWs), lay providers living in the communities they serve, may help close this gap, but the effectiveness and safety of lay CHW-led hypertension care-including independent initiation and titration of medication-remain uncertain. We conducted a 1:1 cluster-randomized trial nested within the Community-Based Chronic Care Lesotho (ComBaCaL) cohort study in 103 rural villages in Lesotho. Following community-based hypertension screening, 547 nonpregnant adults with blood pressure (BP) ≥140/90 mm Hg were enrolled (274 control and 273 intervention). In intervention clusters, lay CHWs independently prescribed and titrated a fixed-dose combination of amlodipine and hydrochlorothiazide, guided by a mobile clinical decision support system. In control clusters, participants were referred to health facilities for standard care. The primary objective was to assess the effectiveness and safety of lay CHW-led care, with the primary outcome defined as BP <140/90 mm Hg at 12 months. In the intention-to-treat analysis (543 participants with 4 exclusions owing to intercurrent pregnancy), BP control was achieved by 156/271 (58%) versus 130/272 (48%) in intervention and control arms, respectively (adjusted odds ratio 1.52, 95% confidence interval 1.01 to 2.29, P = 0.046). A predefined complete case analysis yielded consistent results. No relevant differences in safety outcomes were observed. Among people with uncontrolled hypertension, lay CHW-led, CDSS-supported care was safe and more effective than referral to facility-based professional care. These findings support expanding first-line hypertension management by lay CHWs in remote, resource-limited settings. Clinicaltrials.gov registration: NCT05684055 .</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146180957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1038/s41591-026-04224-w
{"title":"Extracorporeal cross-circulation with genetically modified pig livers in a human decedent model.","authors":"","doi":"10.1038/s41591-026-04224-w","DOIUrl":"https://doi.org/10.1038/s41591-026-04224-w","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1038/s41591-026-04216-w
Capillary blood sampling for the Alzheimer’s disease biomarkers p-tau217, NfL and GFAP correlates with venous measures for the same biomarkers. As capillary p-tau217 accurately classified amyloid burden, it might support remote assessment in large-scale epidemiology to estimate the prevalence of Alzheimer’s disease and enable triage into clinical services and trials.
{"title":"Capillary blood sampling for detecting biomarkers of Alzheimer’s disease","authors":"","doi":"10.1038/s41591-026-04216-w","DOIUrl":"10.1038/s41591-026-04216-w","url":null,"abstract":"Capillary blood sampling for the Alzheimer’s disease biomarkers p-tau217, NfL and GFAP correlates with venous measures for the same biomarkers. As capillary p-tau217 accurately classified amyloid burden, it might support remote assessment in large-scale epidemiology to estimate the prevalence of Alzheimer’s disease and enable triage into clinical services and trials.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"32 2","pages":"429-430"},"PeriodicalIF":50.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1038/s41591-025-04178-5
Dian Zeng, Lorainne Tudor Car, Kamlesh Khunti, Yuanli Liu, Till Bärnighausen, Niels H Chavannes, Pearse A Keane, Holger Kunz, Lan Xue, Joseph J Y Sung, Yih Chung Tham, Lorenzo Righetto, Rupa Sarker, Samuel Yeung Shan Wong, Donald Boudreau, Qionghai Dai, Weiping Jia, Yang Liu, Dinggang Shen, Jia Liu, Weixing Shen, John S Ji, Zhong Wang, Zhiyi Wang, Haibo Wang, Shenglan Tang, Chenyang Pei, Zehua Jiang, Zihao Zou, Yiming Qin, Huating Li, Yasha Wang, Dinesh Visva Gunasekeran, Sabrina Wong, Dong Xu, Ryan Urbanowicz, Liliana Laranjo, Ana Luisa Neves, Nan Liu, Yulan He, Phuoc Van Le, Neil Bressler, Rifat Atun, David C Klonoff, Bin Sheng, Nigam Shah, Josip Car, Tien Yin Wong
{"title":"PRIMARY-AI: outcomes-based standards to safeguard primary care in the AI era.","authors":"Dian Zeng, Lorainne Tudor Car, Kamlesh Khunti, Yuanli Liu, Till Bärnighausen, Niels H Chavannes, Pearse A Keane, Holger Kunz, Lan Xue, Joseph J Y Sung, Yih Chung Tham, Lorenzo Righetto, Rupa Sarker, Samuel Yeung Shan Wong, Donald Boudreau, Qionghai Dai, Weiping Jia, Yang Liu, Dinggang Shen, Jia Liu, Weixing Shen, John S Ji, Zhong Wang, Zhiyi Wang, Haibo Wang, Shenglan Tang, Chenyang Pei, Zehua Jiang, Zihao Zou, Yiming Qin, Huating Li, Yasha Wang, Dinesh Visva Gunasekeran, Sabrina Wong, Dong Xu, Ryan Urbanowicz, Liliana Laranjo, Ana Luisa Neves, Nan Liu, Yulan He, Phuoc Van Le, Neil Bressler, Rifat Atun, David C Klonoff, Bin Sheng, Nigam Shah, Josip Car, Tien Yin Wong","doi":"10.1038/s41591-025-04178-5","DOIUrl":"https://doi.org/10.1038/s41591-025-04178-5","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10DOI: 10.1038/s41591-026-04261-5
Douglas A Simonetto, David Rushlow, Kan Liu, Alberto Calleri, Blake A Kassmeyer, Ryan J Lennon, Puru Rattan, Matthew E Bernard, Gagandeep Singh, Mark E Deyo-Svendsen, Graham King, Stephen K Stacey, Amy Olofson, Alina Allen, Joseph C Ahn, Paul A Friedman, Patrick S Kamath, Zachi I Attia, Peter A Noseworthy, Vijay H Shah
{"title":"Author Correction: Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial.","authors":"Douglas A Simonetto, David Rushlow, Kan Liu, Alberto Calleri, Blake A Kassmeyer, Ryan J Lennon, Puru Rattan, Matthew E Bernard, Gagandeep Singh, Mark E Deyo-Svendsen, Graham King, Stephen K Stacey, Amy Olofson, Alina Allen, Joseph C Ahn, Paul A Friedman, Patrick S Kamath, Zachi I Attia, Peter A Noseworthy, Vijay H Shah","doi":"10.1038/s41591-026-04261-5","DOIUrl":"https://doi.org/10.1038/s41591-026-04261-5","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146157831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：